Additionally, P6-SN38’s efficacy evaluation in the same side-by-side xenograft model showed specific inhibition of NSCLC growth, indicating targetability to tumors overexpressed for EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.